A screen to identify drug resistant variants to target-directed anti-cancer agents
about
Farnesyl transferase inhibitor resistance probed by target mutagenesisTen things you should know about protein kinases: IUPHAR Review 14Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell contextDual tyrosine kinase inhibitors in chronic myeloid leukemia.Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokinesA JAK2 interdomain linker relays Epo receptor engagement signals to kinase activationRefining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.
P2860
Q24684154-D6DDB8CC-802E-4DDB-B69C-1654DD72B9B3Q26849417-052C114B-92E4-4DCF-8276-B005F906A52EQ33927591-6A3C6865-DC53-401E-BBFB-1FA8BCC28AE2Q34695008-0496EAC9-6A7A-4B36-9B07-7340E97642C5Q34890636-916A5F8F-7815-4BA0-9368-F357BA842FE7Q36265601-68A4835B-DFA0-4BF1-9C43-D1C3D90AF414Q36466443-B8928A4F-7BE8-43E1-9501-D0B4CDD79335Q36600241-76E670B4-54BF-4B8B-91B7-F82E2973CA8CQ37162871-30D929FA-EF83-4E69-9DEA-81929E7C9A5EQ37446881-D34D56F9-2BBE-4EAE-894A-E043F2D9D6F1Q37815384-4B94036D-DC50-48E5-A830-332E8DF2D225Q42805035-B34AC741-C9AD-4C1B-B5C4-5D474759C0AEQ46048561-56B7913E-050A-426E-8632-F402E7AE2899
P2860
A screen to identify drug resistant variants to target-directed anti-cancer agents
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A screen to identify drug resistant variants to target-directed anti-cancer agents
@ast
A screen to identify drug resistant variants to target-directed anti-cancer agents
@en
A screen to identify drug resistant variants to target-directed anti-cancer agents
@nl
type
label
A screen to identify drug resistant variants to target-directed anti-cancer agents
@ast
A screen to identify drug resistant variants to target-directed anti-cancer agents
@en
A screen to identify drug resistant variants to target-directed anti-cancer agents
@nl
prefLabel
A screen to identify drug resistant variants to target-directed anti-cancer agents
@ast
A screen to identify drug resistant variants to target-directed anti-cancer agents
@en
A screen to identify drug resistant variants to target-directed anti-cancer agents
@nl
P2093
P2860
P356
P1476
A screen to identify drug resistant variants to target-directed anti-cancer agents
@en
P2093
Mohammad Azam
Sarah L. Opitz
Valentina Nardi
P2860
P2888
P304
P356
10.1251/BPO63
P407
P577
2003-01-01T00:00:00Z
P5875
P6179
1048909782